Targeting Signaling Pathways in Inflammatory Breast Cancer

Xiaoping Wang; Takashi Semba; Lan Thi Hanh Phi; Sudpreeda Chainitikun; Toshiaki Iwase; Bora Lim; Naoto T Ueno

doi:10.3390/cancers12092479

Targeting Signaling Pathways in Inflammatory Breast Cancer

Cancers (Basel). 2020 Sep 1;12(9):2479. doi: 10.3390/cancers12092479.

Authors

Xiaoping Wang^{1

2}, Takashi Semba^{1

2}, Lan Thi Hanh Phi^{1

2

3}, Sudpreeda Chainitikun^{1

2}, Toshiaki Iwase^{1

2}, Bora Lim^{1

2}, Naoto T Ueno^{1

2}

Affiliations

¹ Section of Translational Breast Cancer Research, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
² Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
³ The University of Texas MD Anderson Cancer Center UT Health Graduate School of Biomedical Sciences, Houston, TX 77030, USA.

Abstract

Inflammatory breast cancer (IBC), although rare, is the most aggressive type of breast cancer. Only 2-4% of breast cancer cases are classified as IBC, but-owing to its high rate of metastasis and poor prognosis-8% to 10% of breast cancer-related mortality occur in patients with IBC. Currently, IBC-specific targeted therapies are not available, and there is a critical need for novel therapies derived via understanding novel targets. In this review, we summarize the biological functions of critical signaling pathways in the progression of IBC and the preclinical and clinical studies of targeting these pathways in IBC. We also discuss studies of crosstalk between several signaling pathways and the IBC tumor microenvironment.

Keywords: clinical trials; inflammatory breast cancer; signaling pathways; targeted therapy; tumor microenvironment.

Publication types

Review

Abstract

Publication types

Grants and funding